IFNG and melanoma: Meanwhile, the impact of the statuses of PD-L2, TIS, IFN-gamma, T cell-inflamed GEP, AMP and IRP on objective response was also observed in melanoma patients with combination anti-PD-1 and anti-CTLA-4 immunotherapy (Figure S26).